Literature DB >> 8300524

Involvement of phospholipid end groups of group C Neisseria meningitidis and Haemophilus influenzae type b polysaccharides in association with isolated outer membranes and in immunoassays.

G Arakere1, A L Lee, C E Frasch.   

Abstract

There are several bacterial polysaccharides (PSs) which contain a terminal lipid moiety. It has been postulated that these terminal lipid moieties anchor the PSs to the outer membrane of the bacteria. Our studies have shown that incubation of native PS from group C Neisseria meningitidis or Haemophilus influenzae type b with isolated outer membrane vesicles results in association of a portion of the PS with the vesicles. Removal of the terminal lipid from the PS by treatment with phospholipase A2 or phospholipase D eliminates this association. In other studies, it was shown that delipidated PSs are not suitable as solid-phase antigens in a currently used enzyme-linked immunosorbent assay (ELISA). Measurement of antibody units in the reference sera by using delipidated PSs as antigens in an ELISA yielded negligible absorbance compared with native PSs when methylated human serum albumin was used to coat the PSs to the plate. Nevertheless, phospholipase A2 and phospholipase D treatment did not noticeably affect antigenic epitopes, since soluble group C PS without the terminal lipid bound antibody as effectively as the native PS did, as measured by a competitive inhibition assay. Both hydrophobic and electrostatic interactions are important for the binding of group C N. meningitidis PS to the ELISA plate, while charge interactions seem to be sufficient for binding the more negatively charged H. influenzae type b PS.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8300524      PMCID: PMC205106          DOI: 10.1128/jb.176.3.691-695.1994

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  16 in total

Review 1.  Genetics of capsular polysaccharide production in bacteria.

Authors:  G J Boulnois; I S Roberts
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

2.  Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation.

Authors:  G A Jarvis; N A Vedros
Journal:  Infect Immun       Date:  1987-01       Impact factor: 3.441

Review 3.  Structure and biosynthesis of the capsular antigens of Escherichia coli.

Authors:  B Jann; K Jann
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

Review 4.  The role of bacterial polysaccharide capsules as virulence factors.

Authors:  E R Moxon; J S Kroll
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

5.  Strain-specific variation in the protein and lipopolysaccharide composition of the group B meningococcal outer membrane.

Authors:  C E Frasch; R M McNelis; E C Gotschlich
Journal:  J Bacteriol       Date:  1976-08       Impact factor: 3.490

6.  Evidence for covalent attachment of phospholipid to the capsular polysaccharide of Haemophilus influenzae type b.

Authors:  J S Kuo; V W Doelling; J F Graveline; D W McCoy
Journal:  J Bacteriol       Date:  1985-08       Impact factor: 3.490

7.  Molecular characterization and expression in Escherichia coli of the gene complex encoding the polysaccharide capsule of Neisseria meningitidis group B.

Authors:  M Frosch; C Weisgerber; T F Meyer
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

8.  Protection against group B Neisseria meningitidis disease: preparation of soluble protein and protein-polysaccharide immunogens.

Authors:  C E Frasch; M S Peppler
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

9.  Lipid on capsular polysaccharides of gram-negative bacteria.

Authors:  E C Gotschlich; B A Fraser; O Nishimura; J B Robbins; T Y Liu
Journal:  J Biol Chem       Date:  1981-09-10       Impact factor: 5.157

10.  Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model.

Authors:  C E Frasch; J D Robbins
Journal:  J Exp Med       Date:  1978-03-01       Impact factor: 14.307

View more
  7 in total

1.  Characterization and acceptor preference of a soluble meningococcal group C polysialyltransferase.

Authors:  Dwight C Peterson; Gayathri Arakere; Justine Vionnet; Pumtiwitt C McCarthy; Willie F Vann
Journal:  J Bacteriol       Date:  2011-01-28       Impact factor: 3.490

2.  Analysis of human serum immunoglobulin G against O-acetyl-positive and O-acetyl-negative serogroup W135 meningococcal capsular polysaccharide.

Authors:  Peter C Giardina; Emma Longworth; Renee E Evans-Johnson; Michaelene L Bessette; Hong Zhang; Ray Borrow; Dace Madore; Philip Fernsten
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

3.  Monoclonal antibodies specific for Neisseria meningitidis group B polysaccharide and their peptide mimotopes.

Authors:  J S Shin; J S Lin; P W Anderson; R A Insel; M H Nahm
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

4.  Evaluation of previously assigned antibody concentrations in pneumococcal polysaccharide reference serum 89SF by the method of cross-standardization.

Authors:  N Concepcion; C E Frasch
Journal:  Clin Diagn Lab Immunol       Date:  1998-03

5.  Estimation of group B streptococcus type III polysaccharide-specific antibody concentrations in human sera is antigen dependent.

Authors:  R Bhushan; B F Anthony; C E Frasch
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

6.  CD1 presents antigens from a gram-negative bacterium, Haemophilus influenzae type B.

Authors:  R M Fairhurst; C X Wang; P A Sieling; R L Modlin; J Braun
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

7.  Effect of O acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune responses.

Authors:  David S Berry; Freyja Lynn; Che-Hung Lee; Carl E Frasch; Margaret C Bash
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.